Announced strategic collaboration with Roche, with a $110 million upfront payment, to focus on the research and development of allogeneic CAR-T cell therapies directed to hematologic malignancies
Completed an underwritten public offering adding multiple quality institutional shareholders with gross proceeds of $80.5 million
Well capitalized with cash runway into at least mid-2024
https://finance.yahoo.com/news/poseida-therapeutics-provides-updates-financial-200500053.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.